The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC) The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...
Find MoreJuvenile Idiopathic Arthritis (JIA) is an inflammation in the synovial membranes and the most chronic rheumatoid disorder in children and adolescents. The aim of Juvenile idiopathic arthritis treatment is to control pain; to preserve the range of motion (ROM), muscle strength, and function, manage systemic complica...
Find MoreJuvenile Idiopathic Arthritis July is Juvenile Idiopathic Arthritis Awareness Month, which is dedicated to making everyone aware of arthritis. The most prevalent form of juvenile arthritis is juvenile idiopathic arthritis (JIA). Diagnosis of juvenile idiopathic arthritis can be difficult as joint pain ca...
Find MoreOsivax raises USD 9 M to boost its universal flu vaccine approach France based biotech startup company Osivax, has secured USD 9 million in Series A financing. A Belgian-based firm Noshaq along with Anaxago, an innovative investment platform led the financing. The proceeds will be used to further advance the cl...
Find MoreCould a virus be a treatment therapy? Confusing, isn't it? On the face value, it seems no; but on delving deeper, the confusion dissipates. There have been tireless efforts among a section of scientists to convert certain viruses through biotechnology techniques into anti-disease agents to infect and destroy cancer ...
Find MoreNovartis comes up with an answer for breast cancer with PI3K drug alpelisib Novartis comes up with an answer with its recent data on BYL719 (alpelisib) in combination with fulvestrant. Their alpha-specific drug for PIK3CA mutated HR+/HER2- advanced breast cancer, BYL719 plus fulvestrant nearly doubled the progressio...
Find MoreGilead faces revived lawsuit claiming it sidestepped FDA with HIV drug imports Gilead Sciences thought it had prevailed in a whistleblower lawsuit alleging it circumvented FDA rules to use a China-made active ingredient in three top HIV meds, rather than a higher-priced version from South Korea that the agency had a...
Find MoreMerck's Remicade discounting put squeeze on biosims—and broke U.K. law, officials say Under biosimilar assault in Europe, Merck rolled out cut-rate deals on Remicade to defend its brand from cheaper options, then-brand-new to the market. Now, the U.K.’s competition authority claims the pharma giant “broke competitio...
Find MoreAstraZeneca's new benralizumab helps severe asthma patients cut back on steroids AstraZeneca's respiratory candidate benralizumab can help some severe asthma patients cut down on—or even stop—the unsavory steroid pills they use daily to stave off attacks, a new study showed. Dubbed Zonda, the phase 3 trial found tha...
Find MoreTesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib Tesaro’s closely watched ovarian cancer drug niraparib—now dubbed Zejula—won an FDA nod on 27th March, months before its scheduled decision date. Apart from getting approval, Zejula also got a broader label than its head-to-head rival,...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.